Nirsevimab effectiveness for RSV in Chilean infants
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This study tests if the medicine Nirsevimab can help prevent severe RSV (a common winter virus) in infants in Chile. It is for babies born at specific times in 2023–2024, especially those born early or with health problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were born in Chile between October 1, 2023 and September 30, 2024
- You were born very early (before 29 weeks of pregnancy) between July 1 and October 1, 2023
- You were born with lung problems of prematurity (BPD), at 32 weeks or less, or weighed less than 1.5 kg at birth, between April 1 and October 1, 2023
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether the drug nirsevimab can reduce hospitalizations caused by RSV (a common respiratory virus) in babies under 1 year old. If your baby has a lung infection like bronchiolitis or pneumonia, this trial may help understand how well the medicine works.
This trial tests a preventive medicine called nirsevimab given to infants to see how well it protects them from a common serious lung infection. It is offered as part of regular check-ups for babies born during a specific time period.
This trial tests giving a medicine called nirsevimab to newborns and a possible vaccine to pregnant mothers to prevent RSV, a serious lung infection in babies. It checks if combining both is safe and works better than nirsevimab alone.
This study looks at how well the new nirsevimab vaccine works against bronchiolitis in babies. If your infant has their first bout of bronchiolitis and gets a nose swab, they may be able to help researchers understand how the virus spreads and how to better protect other babies.
This trial looks at how well the drug nirsevimab works for babies hospitalized with RSV bronchiolitis. It also studies the body's immune response and the baby's environment. The goal is to see if nirsevimab can help infants recover from this serious lung infection.
This study looks at how well RSV vaccines or antibody shots protect babies from severe respiratory infections. If your baby is under 1 year old, lives in Connecticut, and gets sick with a respiratory infection, they may be able to join.
Hear when a new RSV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.